Cutaneous manifestations of antiphospholipid syndrome: A review of the clinical features, diagnosis and management

Acta Reumatologica Portuguesa

Volumn 38, Issue 1, 2013, Pages 10-18

  Pinto Almeida, Teresa ^a   Caetano, Mónica ^a,b   Sanches, Madalena ^a   Selores, Manuela ^a,b  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antiphospholipid syndrome; Dermatology; Diagnosis; Review; Skin

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; HUMAN; SKIN DISEASE;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; SKIN DISEASES;

EID: 84876375540     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Hughes GR. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 1983; 287: 1088-1089.
2. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syn- drome. J Rheumatol 1986; 13: 486-489.
3. Wong RC, Favloro EJ. Clinical features, diagnosis and mana- gement of the antiphospholipid syndrome. Semin Thromb He- most 2008;34:295-304.
4. Gibson GE, Su W, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36: 970-982.
5. Grob JJ, Bonerandi JJ. Cutaneous manifestations associated with the presence of the lupus anticoagulant. J Am Acad Der- matol 1986; 15: 211-219.
6. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of di- sease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
7. Levine JS, Branch DW, Rauch J. The Antiphospholipid syn- drome. N Eng J Med 2002; 346: 752-763.
8. Asherson RA, Cervera R, Piette JC et al. Catastrophic anti- phospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207.
9. Stojanovich L, Marisavljevic D, Rovensky J et al. Clinical and laboratory features of the catastrophic antiphospholipid syn- drome. Clin Rev Allergy Immunol 2009;36:74-79.
10. Petri M. Epidemiology of the antiphospholipid antibody syn- drome. J Autoimmun 2000; 15: 145-151.
11. Jara LJ, Medina G, Vera-Lastra O et al. The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 2005; 14: 607-612.
12. Wilson WA, Gharavi AE, Koike T et al. International consen- sus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international works- hop. Arthritis Rheum 1999; 42: 1309-1311.
13. Bart PA. When should consider antiphospholipid syndrome? Rev Med Suisse 2008; 16: 97-99.
14. Miyakis S, Lockshin MD, Atsumi T et al. International consen- sus statement on an update of the classification criteria for de- finite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
15. Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108: 263-271.
16. Tincani A, Allegri F, Sanmarco M et al. Anticardiolipin antibo- dy assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-583.
17. Wong RC, Gillis D, Adelstein S et al. Consensus guidelines on anticardiolipin antibody testing and reporting. Pathology 2004; 36: 63-68.
18. Reber G, Tincani A, Sanmarco M et al. Proposals for the mea- surement of anti-beta-2-glycoprotein I antibodies. Standardi- zation group of the European Forum on Antiphospholipid An- tibodies. J Thromb Haemost 2004; 2: 1860-1862.
19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diag- nosis of lupus anticoagulants: an update. On behalf of the Sub- committee on Lupus Anticoagulant/Antiphospholipid Antibo- by of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
20. Pengo V, Banzato A, Bison E et al. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010; 19:428-431.
21. Devreese K, Hoylaerts MF. Laboratory diagnosis of the Anti- phospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009; 83: 1-16.
22. Tincani A, Filippini M, Scarsi M et al. European attempts for the standardization of the antiphospholipid antiboidies. Lupus 2009; 18: 913-919.
23. Pengo V, Biasiolo A. The risk of overdiagnosis of antiphospho- lipid antibody syndrome. Thromb Haemost 2001; 86: 933.
24. Pengo V, Ruffatti A, Iliceto S. The diagnosis of the antiphos- pholipid syndrome. Pathophysiol Haemost Thromb 2006; 35: 175-180.
25. Meroni PL, Tincani A, Alarcón-Riquelme ME et al. European fo- rum on antiphospholipid antibodies: research in progress. Lu- pus 2009; 18: 924-929.
26. Asherson RA, Khamashta MA, Ordi-Ros J et al. The primary antiphospholipid syndrome: major clinical and pathological features. Medicine (Baltimore) 1989; 68: 366-374.
27. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicentre study of 114 patients. Am J Med 1994; 96: 3-9.
28. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphos- pholipid syndrome. J Rheumatol 1989; 16: 482-486.
29. Francès C, Niang S, Laffitte E et al. Dermatologic manifesta- tions of the antiphospholipid syndrome: two hundred conse- cutive cases. Arthritis Rheum 2005; 52: 1785-1793.
30. Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions asso- ciated with circulating lupus anticoagulant. Br J Dermatol 1989; 120: 419-429.
31. Cervera R, Asherson RA, Acevedo ML et al. Antiphospholipid syndrome associated with infections: clinical and microbiolo- gical characteristics of 100 patients. Ann Rheum Dis 2004; 63: 1312-1317.
32. Diógenes MJ, Diógenes PC, Carneiro RM et al. Cutaneous ma- nifestations associated with antiphospholipid antibodies. Int J Dermatol 2004; 43: 632-637.
33. Gibbs MB, English JC 3rd, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005; 52: 1009-10
34. Uthman IW, Khamashta MA. Livedo racemosa: a striking der- matological sign for the antiphospholipid syndrome. J Rheu- matol 2006; 33: 2379-2382.
35. Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180-185.
36. Levine SR, Langer SL, Albers JW, Welch KM. SneddonBerkeley-Book.-1..notdefs syn- drome: an antiphospholipid antibodies syndrome. Neurology 1988; 38: 798-800.
37. Kalashnikova LA, Nasonov EL, Stoyanovich LZ et al. SneddonBerkeley-Book.-1..notdefs syndrome and the primary antiphospholipid syndrome. Cere- brovasc Dis 1994;4:76-82.
38. Merino AJ, Arenzana J. Primary antiphospholipid syndrome as- sociated with Sneddon syndrome. Rev Clin Esp. 1992; 191: 226.
39. Vargas JA, Yebra M, Pascual ML, Manzano L. Sneddon syndro- me and primary antiphospholipid syndrome: are they the same entity? Med Clin (Barc) 1990; 94: 597.
40. Francès C, Piette JC. The mystery of Sneddon syndrome:rela- tionshio with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139-143.
41. Sinharay R. SneddonBerkeley-Book.-1..notdefs syndrome: additional neurological fea- ture on antiphospholipid (HughesBerkeley-Book.-1..notdef) syndrome. Postgrad Med J 2003; 79: 550.
42. Gantcheva M, Tsankov N. Livedo reticularis and cerebrovas- cular accidents (SneddonBerkeley-Book.-1..notdefs syndrome) as a clinical expression of antiphospholipid syndrome. J Eur Acad Dermatol Venereol 1999; 12: 157-160.
43. Francès C, Papo T, Wechsler B et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999; 78: 209-219.
44. Fetoni V, Grisoli M, Salmaggi A et al. Clinical and neuroradio- logical aspects of SneddonBerkeley-Book.-1..notdefs syndrome and primary antiphos- pholipid syndrome. A follow-up study. Neurol Sci 2000; 21: 157-164.
45. Robson K, Piette W. The presentation and differencial diagno- sis of cutaneous vascular occlusion syndromes. Adv Dermatol 1999; 15: 153-182.
46. Naldi L, Marchesi L, Finazzi G et al. Antiphospholipid antibo- dies and necrotizing purpura. Dermatologica 1990; 180: 272-275.
47. Sharkey MP, Daryanani II, Gillett MB, Jones SK. Localized cu- taneous necrosis associated with the antiphospholipid syndrome. Australas J Dermatol 2002; 43: 218-220.
48. Jou IM, Liu MF, Chao SC. Widespread cutaneous necrosis as- sociated with antiphospholipid syndrome. Clin Rheumatol 1996; 15: 394-398.
49. Abernethy ML, McGuinn JL, Callen JP. Widespread cutaneous necrosis as the initial manifestation of the antiphospholipid syndrome. J Rheumatol 1995; 22: 1380-1383.
50. Rossini J, Roverano S, Graf C, Paira S. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol 2002; 8: 326-331.
51. Creamer D, Hunt BJ, Black MM. Widespread cutaneous ne- crosis occurring in association with the antiphospholipid syn- drome: a report of two cases. Br J Dermatol 2000; 142: 1199-1203.
52. Stephansson EA, Niemi KM, Jouhikainen T et al. Lupus anti- coagulant and the skin. Acta Derm Venereol (Stockh) 1991; 71: 416-422.
53. Schlesinger IH, Farber GA. Cutaneous ulcerations resembling pyoderma gangrenosum in the primary antiphospholipid syn- drome: a report of two additional cases and review of the lite- rature. J La State Med Soc 1995; 147: 357-361.
54. Goldberg DP, Lewis VL Jr, Koenig WJ. Antiphospholipid anti- body syndrome: a new cause of nonhealing skin ulcers. Plast Reconstr Surg 1995; 95: 837-841.
55. Gertner E, Lie JT. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the an- tiphospholipid syndrome. J Rheumatol 1994; 21: 2159-21
56. Asherson RA, Cervera R, Shoenfeld Y. Peripheral vascular oc- clusions leading to gangrene and amputations in antiphos- pholipid antibody positive patients. Ann N Y Acad Sci 2007; 1108: 151-129.
57. Asherson RA, Cervera R, Klumb E et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum. 2008; 38: 124-131.
58. Frances C, Piette J, Saada V et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome. Lupus 1994; 3: 123-128.
59. Asherson R. Subungual splinter hemorrhages: a new sign of the antiphospholipid coagulopathy? Ann Rheum Dis 1990; 49: 268.
60. Kujic F, Lloyd M, Cuadrado MJ et al. Prevalence and clinical sig- nificance of subungual splinter haemorrages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1995; 13:327-331.
61. Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Der- matol 2007; 29: 44-45.
62. Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical Spectrum. Curr Rheumatol Rep 2002; 4: 83-89.
63. Grob JJ, San Marco M, Aillaud MF et al. Unfading acral micro- livedo: a discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome. J Am Acad Der- matol 1991; 24: 53-58.
64. Asherson RA, Jacobelli S, Rosenberg H et al. Skin nodules and macules resembling vasculitis in the antiphospholipid syndrome - a report of two cases. Clin Exp Dermatol 1992; 17: 266-2
65. Ishikawa O, Takahashi A, Tamura A, Miyachi Y. Cutaneous pa- pules and nodules in the diagnosis of antiphospholipid syn- drome. Br J Dermatol 1999; 140: 725-729.
66. Tomb R, Maalouf E, Attoui S. Cutaneous nodular lesions and antiphospholipid syndrome. Ann Dermatol Venereol 2008; 135: 484-487.
67. Bard JW, Winkelmann RK. Livedo vasculitis: segmental hyali- nizing vasculitis of the dermis. Arch Dermatol 1967; 96: 489-499.
68. Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol 1999; 140: 131-135.
69. McCalmontC.S., McCalmont TH, Jorizzo JL et al. Livedo vascu- litis: vasculitis or thrombotic vasculopathy? Clin Exp Derma- tol 1992; 17: 4-8.
70. Hairston B, Davis M, Pittelkow M et al. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Derma- tol 2006; 142: 1413-1418.
71. Grasland A, Crickx B, Blanc M et al. Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies. Ann Med Interne (Paris) 2000; 151: 408-410.
72. Llamas P, Yebra M, Berrocal E et al. Idiopathic white atrophy and the primary antiphospholipid syndrome: a promise still anfulfilled. Rev Clin Esp 1996; 196: 342-343.
73. Weinstein S, Piette W. Cutaneous manifestations of antiphos- pholipid antibody syndrome. Hematol Oncol Clin N Am 2008; 22: 67-77.
74. Englert H, Hawkes C, Boey M et al. DegosBerkeley-Book.-1..notdef disease: association with anticardiolipin antibodies and lupus anticoagulant. Br Med J 1984; 289: 576.
75. Assier H, Chosidow O, Piette J et al. Absence of antiphospho- lipid and antiendothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases. J Am Acad Dermatol 1995; 33: 831-833.
76. Hodak E, Shamai Lubovitz O, David M et al. Immunologic ab- normalities associated with primary anetoderma. Arch Der- matol 1992; 128: 799-803.
77. Disdier P, Harle J, Andrac L et al. Primary anetoderma associa- ted with antiphospholipid syndrome. J Am Acad Dermatol 1994; 30: 133-134.
78. de Souza E, Christofoletti P, Cintra M. Anetoderma associated with primary antiphospholipid syndrome. J Am Acad Derma- tol 2007; 56: 881-882.
79. Bilen N, Bayramgurler D, Sikar A et al. Anetoderma associated with antiphospholipid syndrome and systemic lupus erythe- matosus. Lupus 2003; 12: 714-716.
80. Hodak E, David M. Primary anetoderma and antiphospholipid antibodies-review of the literature. Clin Rev Allergy Immunol 2007; 32: 162-166.
81. Hodak E, Feuerman H, Moland Y et al. Primary anetoderma: a cutaneous sign of antiphospholipid antibodies. Lupus 2003; 12: 564-568.
82. Sparsa SA, Piette JC, Weschsler B et al. Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol 2003; 49: 1008-1012.
83. Lie J. Vasculopathy in the antiphospholipid syndrome: throm- bosis or vasculitis or both? J Rheumatol 1989; 16: 713-715.
84. Lie J. The distinction between vasculitis coincidental with one that is causally relates to the antiphospholipid syndrome. Arth- ritis Rheum 1992; 35: 15-40.
85. Lie J. Vasculitis in the antiphospholipid syndrome: culprit or consort? J Rheumatol 1994; 21: 397-399.
86. Cervera R, Asherson AR, Lie JT. Clinicopathologic correlation of antiphospholipid syndrome. Semin Arthritis Rheum 1995; 24: 262-272.
87. Creamer D, Black MM, Calonje E. Reactive angioendothelio- matosis in association with the antiphospholipid syndrome. J Am Acad Dermatol 2000; 42: 903-906.
88. Thai KE, Barret W, Kossard S. Reactive angioendotheliomato- sis in the setting of antiphospholipid syndrome. Australas J Dermatol 2003; 44: 151-155.
89. Kriseman YL, Nash JW, Hsu S. Criteria for the diagnosis of an- tiphospholipid syndrome in patients presenting with derma- tological symptoms. J Am Acad Dermatol 2007; 57: 112-1
90. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun 2009; 33: 92-98.
91. Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multi- systemic disease. Clin Exp Rheumatol 2009; 27: 668-677.
92. Brunner HI, Chan WS, Ginsberg JS, Fekdman BM. Longterm anticoagulation is preferable for patients with antiphospholipid syndrome - result of a decision analysis. J Rheumatol 2002; 29: 490-501.
93. Lim W, Crowther MA, Eikelboom JW. Management of anti- phospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050-1057.
94. Gerosa M, Chighizola C, Meroni PL. Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibo- dies? Yes (in some cases). Intern Emerg Med 2008; 3: 201-2
95. Erkan D, Yazici Y, Peterson MG et al. A cross sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41: 924-929.
96. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary throm- bosis prevention in the antiphospholipid syndrome: a rando- mized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382-2391.
97. Herenge T, Lambert M, Hachulla E et al. Influence of aspirin on the clinical outcomes of 103 antiphospholipid antibodies-po- sitive patients. Lupus 2008; 17: 11-15.
98. Espinosa G, Cervera R. Recent trends in the management of antiphospholipid syndrome (Hughes syndrome). Drugs Today (Barc) 2010; 46: 39-47.
99. Asherson RA, Francès C, Iaccarino L et al. The antiphospholi- pid antibody syndrome: diagnosis, skin manifestations and cur- rent therapy. Clin Exp Rheumatol 2006; 24: 46-51.
100. Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004-3008.